Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Werewolf Therapeutics (HOWL) stock

Learn how to easily invest in Werewolf Therapeutics stock.

Werewolf Therapeutics, Inc
NASDAQ: HOWL - USD
BIOTECHNOLOGY
$19.45
+$1.14 (+6.23%)

Werewolf Therapeutics, Inc is a biotechnology business based in the US. Werewolf Therapeutics shares (HOWL) are listed on the NASDAQ and all prices are listed in US Dollars. Werewolf Therapeutics employs 28 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Werewolf Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HOWL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Werewolf Therapeutics stock price (NASDAQ: HOWL)

Use our graph to track the performance of HOWL stocks over time.

Werewolf Therapeutics shares at a glance

Information last updated 2021-07-23.
52-week range$11.23 - $21.67
50-day moving average $15.32
200-day moving average $14.59
Wall St. target price$26.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Werewolf Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Werewolf Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Werewolf Therapeutics financials

Gross profit TTM $0
Return on assets TTM -23.72%
Return on equity TTM -30.39%
Profit margin 0%
Book value N/A
Market capitalisation $504.8 million

TTM: trailing 12 months

Shorting Werewolf Therapeutics shares

There are currently 1.2 million Werewolf Therapeutics shares held short by investors – that's known as Werewolf Therapeutics's "short interest". This figure is 39.1% up from 831,209 last month.

There are a few different ways that this level of interest in shorting Werewolf Therapeutics shares can be evaluated.

Werewolf Therapeutics's "short interest ratio" (SIR)

Werewolf Therapeutics's "short interest ratio" (SIR) is the quantity of Werewolf Therapeutics shares currently shorted divided by the average quantity of Werewolf Therapeutics shares traded daily (recently around 152930.55555556). Werewolf Therapeutics's SIR currently stands at 7.56. In other words for every 100,000 Werewolf Therapeutics shares traded daily on the market, roughly 7560 shares are currently held short.

To gain some more context, you can compare Werewolf Therapeutics's short interest ratio against those of similar companies.

However Werewolf Therapeutics's short interest can also be evaluated against the total number of Werewolf Therapeutics shares, or, against the total number of tradable Werewolf Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Werewolf Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Werewolf Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.1574% of the tradable shares (for every 100,000 tradable Werewolf Therapeutics shares, roughly 157 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Werewolf Therapeutics.

Find out more about how you can short Werewolf Therapeutics stock.

Werewolf Therapeutics share dividends

We're not expecting Werewolf Therapeutics to pay a dividend over the next 12 months.

Werewolf Therapeutics overview

Werewolf Therapeutics, Inc. , a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. .

Stocks similar to Werewolf Therapeutics

Frequently asked questions

What percentage of Werewolf Therapeutics is owned by insiders or institutions?
Currently 12.923% of Werewolf Therapeutics shares are held by insiders and 61.666% by institutions.
How many people work for Werewolf Therapeutics?
Latest data suggests 28 work at Werewolf Therapeutics.
When does the fiscal year end for Werewolf Therapeutics?
Werewolf Therapeutics's fiscal year ends in December.
Where is Werewolf Therapeutics based?
Werewolf Therapeutics's address is: 1030 Massachusetts Avenue, Cambridge, MA, United States, 02138

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site